Overview
Aclaris Therapeutics, Inc., based in the United States, operates in the biopharmaceutical industry where it focuses on developing novel drug candidates and technologies to address unmet needs in medical and aesthetic dermatology as well as immunodermatology. The company is particularly acclaimed for its pipeline projects aimed at treating skin disorders like alopecia areata, vitiligo, and common warts. Among their various stages of research and development, Aclaris emphasizes innovation in small molecule therapeutics, seeking to harness scientific advancements to deliver tangible solutions for complex skin conditions. Their strategic approach involves identifying and rapidly advancing a portfolio of proprietary compounds with potential significant commercial prospects in dermatologically related conditions.
Basic Stats
The share price of Aclaris Therapeutics, Inc. as of September 4, 2025 is $2.07 / share. This is an increase of 12.50% from the prior week. The market cap (or net worth) of Aclaris Therapeutics, Inc. as of September 4, 2025 is $224.24 MM.
The Factor Analysis chart (below right) shows a view of Aclaris Therapeutics, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 224.24 MM |
| EV | 199.38 MM |
| Shares Out. | 108.33 MM |
| Earnings Date | |
| EPS (TTM) | -1.24 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 0.80 |
| Short Shares Avail. | 0.85 MM |
| Short Interest | 5.98 MM |
| Short Float | 8.23 % |
| Days to Cover | 8.07 days |
| Risk Free Rate | 4.22 % |
| Price Change (1 yr) | 77.35 % |
| Volatility (1 yr) | 1.01 |
| Beta | 1.12 |
| Sharpe Ratio (1 yr) | 0.72 |
| Sortino Ratio (1 yr) | 1.80 |
| PE Ratio | -1.67 |
| Price/Book | 1.70 |
| Price/TBV | 1.71 |
| Book/Market | 0.59 |
| EBIT/EV | -0.68 |
| EBIT(3yr avg)/EV | -0.50 |
| ROA | -0.84 |
| ROE | -1.01 |
| ROIC | -1.00 |
| CROIC | 0.02 |
| OCROIC | -0.07 |
| Implied Volatility | 102.85 % |
| Put/Call OI Ratio | 0.02 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Aclaris Therapeutics, Inc. is $8.01. The forecasts range from a low of $2.02 to a high of $16.80. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Aclaris Therapeutics, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-12-14 | Stifel | Buy | Initiate | |
| 2022-12-01 | Goldman Sachs | Buy | Initiate | |
| 2022-10-06 | BTIG | Buy | Initiate | |
| 2021-06-16 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-06-15 | Piper Sandler | Overweight | Initiate | |
| 2021-04-21 | HC Wainwright & Co. | Buy | Initiate | |
| 2021-03-04 | SVB Leerink | Outperform | Maintains | |
| 2021-01-20 | SVB Leerink | Outperform | Maintains | |
| 2019-10-23 | SVB Leerink | Market Perform | Outperform | Upgrade |
| 2019-10-22 | SVB Leerink | Market Perform | Outperform | Upgrade |
| 2019-09-06 | JMP Securities | Market Outperform | Market Perform | Downgrade |
| 2019-08-09 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2019-06-27 | SVB Leerink | Outperform | Market Perform | Downgrade |
| 2019-05-06 | SVB Leerink | Outperform | Initiate | |
| 2018-10-16 | JMP Securities | Market Perform | Market Outperform | Maintains |
| 2018-03-28 | Leerink Swann | Outperform | Outperform | Maintains |
| 2018-03-13 | Leerink Swann | Outperform | Outperform | Maintains |
| 2018-02-09 | Guggenheim | Buy | Initiate | |
| 2017-06-16 | Cantor Fitzgerald | Overweight | Initiate | |
| 2016-11-29 | Leerink Swann | Outperform | Initiate | |
| 2016-09-30 | JMP Securities | Market Perform | Initiate | |
| 2016-09-19 | Jefferies | Buy | Maintains | |
| 2016-08-12 | Jefferies | Buy | Maintains | |
| 2016-06-10 | Guggenheim | Buy | Initiate | |
| 2016-03-16 | Citigroup | Buy | Maintains | |
| 2015-11-02 | William Blair | Outperform | Initiate | |
| 2015-11-02 | Jefferies | Buy | Initiate | |
| 2015-11-02 | Citigroup | Buy | Initiate | |
| 2023-02-07 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2023-03-07 | Goldman Sachs | Buy | Maintains | |
| 2023-03-07 | BTIG | Buy | Maintains | |
| 2023-03-07 | HC Wainwright & Co. | Buy | Maintains | |
| 2023-02-24 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-06-14 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-11-13 | William Blair | Outperform | Market Perform | Downgrade |
| 2023-11-13 | Stifel | Buy | Hold | Downgrade |
| 2023-10-04 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-09-19 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-12-18 | Stifel | Hold | Hold | Maintains |
| 2023-11-14 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-11-14 | Cantor Fitzgerald | Overweight | Neutral | Downgrade |
| 2023-10-03 | Evercore ISI Group | Outperform | Initiate | |
| 2023-08-08 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-09-14 | Stifel | Buy | Buy | Maintains |
| 2023-10-09 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-09-19 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-01-11 | BTIG | Buy | Neutral | Downgrade |
| 2024-01-22 | HC Wainwright & Co. | Buy | Neutral | Downgrade |
| 2023-12-29 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-05-09 | Scotiabank | Sector Outperform | Sector Outperform | Maintains |
| 2024-07-22 | HC Wainwright & Co. | Neutral | Reiterate | |
| 2024-12-23 | HC Wainwright & Co. | Neutral | Buy | Upgrade |
| 2024-08-19 | HC Wainwright & Co. | Neutral | Reiterate | |
| 2024-11-19 | BTIG | Neutral | Buy | Upgrade |
| 2024-11-18 | Piper Sandler | Neutral | Overweight | Upgrade |
| 2024-09-17 | HC Wainwright & Co. | Neutral | Reiterate | |
| 2024-11-19 | Jefferies | Hold | Buy | Upgrade |
| 2024-11-19 | Leerink Partners | Market Perform | Outperform | Upgrade |
| 2025-06-25 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-03-07 | Scotiabank | Sector Outperform | Initiate | |
| 2025-03-18 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-05-14 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-05-28 | Wedbush | Outperform | Initiate |
